Skip to content

Inspection Record

MSD Ireland (Carlow) — FDA 483 Findings

US FDAInspected 2025-04-01Published 2026-10-26 3 findingsDeviation, CAPA, and investigationAseptic processing and sterility assurance

Inspectors Laurel A Beer · Travis S BradleyThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Deviation, CAPA, and investigation

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

2Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

3Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

MSD Ireland (Carlow) company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.